Philip (Phil) Powell Purchases 50,000 Shares of INOVIQ Ltd (ASX:IIQ) Stock

INOVIQ Ltd (ASX:IIQ) insider Philip (Phil) Powell acquired 50,000 shares of the company’s stock in a transaction on Monday, March 10th. The stock was acquired at an average cost of A$0.35 ($0.22) per share, for a total transaction of A$17,500.00 ($11,006.29).

INOVIQ Price Performance

The company has a quick ratio of 9.52, a current ratio of 7.07 and a debt-to-equity ratio of 2.02. The firm has a market cap of $47.40 million, a P/E ratio of -6.02 and a beta of 2.04.

INOVIQ Company Profile

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample.